Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker

摘要: Abstract Objective. (1) To identify and (2) validate genes that are up-regulated in ovarian cancer, (3) to investigate whether the activity of a candidate gene, creatine kinase B (CKB) is elevated pre-operative sera from cancer patients compared with benign pelvic masses normal controls. Methods. MICROMAX cDNA microarray system RNA derived pooled cell lines ovary surface epithelial cells (HOSE) were used differentially expressed genes. Using both tissue obtained through laser capture microdissection (LCM), we performed quantitative PCR order up-regulation one these genes, (CKB). commercially available enzyme assay, CKB was measured serum samples 45 patients, 49 mass, as well 37 Statistical analysis preformed using an unpaired Student's t test. Results. Microarray technology revealed gene expression had HOSE ratio 18. levels CKB, by real-time PCR, mean (and standard error) 36-fold (8.4) 22.75-fold (10.45) microdissected cells. In serum, (±standard cases 24.7 U/L units (±5.1) 9.6 (±1.6) for mass ( P = 0.0088) 8.5 (1.7) controls 0.0096). Conclusions. offers method tumor biomarkers potential clinical usefulness. Our data indicated vitro vivo significantly including those stage I disease. These findings suggest role marker early diagnosis.